15^th International Pharmaceutical Microbiology and Biotechnology Conference June 21-23, 2017 London, UK

Graduated in Pharmacy and Biochemistry at the Federal University of Paraná (1992) and did a master's degree in Pharmaceutical Sciences at the Federal University of Paraná (2001). Conclude its PhD in Health Sciences at PUCPR in 2015. He is currently associate professor of the Pontifical Catholic University of Parana, where he coordinates since 1997 the Specialization Course in Microbiology and from 2009 to 2010 coordinated the Specialization Course in Clinical Analysis. Since 2012 also operates in PUC Agency for Science, Technology and Innovation. He is a pharmacist at the Molecular Bacteriology Sector of LACEN-PR, consultant at a large reference clinical lab. DB (Diagnóstico do Brasil) Division of Microbiology. He is formerly Director of the Central Laboratory of the State of Paraná, 2003-2010; past President of the Brazilian Society of Clinical Analysis- Paraná, for 4 years (2004-2008). Coordinated the Specialization in Clinical Laboratory Management. It has expertise in bacteriology and Specialist in Clinical Analysis and participates as a reviewer of the journals: Brazilian Journal of Infectious Diseases, Brazilian Journal of Microbiology and Journal of Clinical Microbiology. He has experience in the following subjects: Clinical Analysis and Management Laboratory, focusing on Clinical Microbiology and Public Health, acting on the following topics: laboratory and microbiological diagnosis; bacterial resistance, molecular epidemiology and nosocomial infections; non-fermentative bacteria; advanced bacterial identification (genome sequencing); clinical laboratory management and innovation and research in health technologies. Member of BrCAST (Brazilian Committee on Antimicrobial Susceptibility Test) and Board of Microbial Resistance in Technical Health Services - (CATREM) ANVISA.

Diagnostic Microbiology

Edvaldo Antonio Ribeiro Rosa is a full Professor of Microbiology at the Pontifical Catholic University of Parana (PUCPR). He is the Leader of the Xenobiotics Research Unit, at PUCPR. His research interests are “on microbial biotransformation of xenobiotics to obtain new bioactive molecules and in the modulation of microbial virulence factors by drugs”.

Microbiology

Jorg Kreuter studied Pharmacy at the Philipps-University Marburg, Germany and got his PhD in 1974 as well as his Habilitation (Science Doctor) in 1982 at the Eidegenössische Technische Hochschule (ETH) in Zürich, Switzerland. In 1977, he was working as a Postdoc at the University of Kansas in Lawrence and in 1979, at the University of Michigan in Ann Arbor. In 1983, he was a Visiting Professor at the University of Wisconsin in Madison and in 1984 he became a Professor at the Goethe-University of Frankfurt, Germany. He was Dean twice, between 1988-1989 and 1997-1998. He is one of the pioneers in nanoparticles and has over 300 publications.

Medical Microbiology

Serena Mazzucchelli, PhD, research associate at the University of Milan. She received her bachelor degree in Biological Sciences in 2004, degree in Biology in 2006 and PhD in Biological Sciences in 2009 at the Department of Biotechnology and Biosciences (University of Milan-Bicocca-Italy). From 2009 to 2012 she has a post-doc fellowship at the Department of Biomedical and Clinical Sciences “L. Sacco” (University of Milan-Italy). From 2012 to 2015 she is researcher at the “L. Sacco” University Hospital. Today, SM is carrying out her research activity focused on the development of nanodevices for diagnosis and therapy of breast cancer at the Department of Biomedical and Clinical Sciences “L. Sacco” (University of Milan).

Biochemistry, nanobiotechnology and nanomedicine. SM research activity is focused on the study of nanoparticle interaction with tumor cells aimed at the development of nanodevices for diagnosis and therapy of breast cancer.

Gulay Buyukkoroglu has completed her Ph.D at the age of 33 years from Anadolu University and postdoctoral studies from University of London The School of Pharmacy on transcutaneous DNA vaccination. She is head of Pharmaceutical Biotechnology at Anadolu University Faculty of Pharmacy. She is working on gene delivery systems, new cancer drug delivery systems with siRNA and specific antibodies attached drug delivery systems and DNA vaccination.

Pharmaceutical Microbiology

Suleiman Al-Obeid has completed his Residency in Internal Medicine at Damascus University, School of Medicine in Syria in 1977 and at the University of Paris VI in France. He has completed his Clinical and Microbiological research on the Mechanism of Bacterial Resistance in the Molecular Research Laboratory at the University of Paris VI, Department Of Microbiology, School of Medicine where he completed his PhD in 1990. He was an Assistant Professor at Damascus University, School of Medicine since 1991. He is a Member in the French & European Society of Microbiology. He has several scientific papers and projects either presented or published. He is an internationally recognized expert in many areas including internal medicine, infectious diseases & clinical microbiologic research. He is a Reviewer for several international journal of medicine in clinical microbiology and infection control.

Microbiology and Bacteriology

Dr. Sandle is a tutor with the School of Pharmacy and Pharmaceutical Sciences, University of Manchester and is Head of Microbiology at Bio Products Laboratory. In addition, Dr. Sandle serves on several national and international committees relating to pharmaceutical microbiology and cleanroom contamination control. He is a committee member of the Pharmaceutical Microbiology Interest Group (Pharmig).

Pharmaceutical Microbiology

Daniel founded BioOutsource in 2007 with a team which included some former colleagues from Q-One Biotech. As Chief Scientist he has developed a successful team which is now seen as one of the leading providers for bioanalytical services globally and has gained a reputation for successful contract research in the biosimilar industry.. He has also held senior positions in the fields of contract research (BioReliance Europe) and manufacturing (MedImmune). Daniel has a keen interest in Biosimilars and from his time with MedImmune working on the FluMist project he has retained an interest in virus vaccines.

Biosimilars, Monoclonal Antibodies and Virus Vaccines

Professor Gregory Gregoriadis is the Founder (1997) of Xenetic Biosciences Inc, the creator of the company's PolyXen (polysialic acid) and ImuXen (liposome) technologies and a SAB member. He served as a Board member, Director and CSO (1997-2015). He was Head of the Centre for Drug Delivery Research(1990-2001) at University College London, and Head of the Liposomes Group at the Medical Research Council (1972-1990). In 1971 he introduced(with B. Ryman) liposomes for drug and vaccine delivery, and in 1991 introduced polysialic acid to improve the pharmacokinetics and pharmacodynamics of protein and peptide drugs. He has published nearly 400 research papers, reviews and articles, and 27 books on drug and vaccine delivery. Gregory's achievements have been honoured with the Controlled Release Society Founders Award (1994), the A.D. Bangham FRS Life Achievement Award (1995), a Fellowship in the American Association of Pharmaceutical Scientists (1998), a Fellowship in the Controlled Release Society(2013), a DSc from the University of London (2001), a Journal of Drug Targeting Life Achievement Award (2008), a Fellowship in the Academy of Pharmaceutical Scientists (2008), and the Founders Award of Liposome Research Days (2010), all for exceptional contributions to the field of drug and vaccine delivery. Gregory's seminal contributions are also reflected in his founding (1978) of the Gordon Research Conference series 'Drug Carriers in Medicine and Biology', his directorships of the NATO Advanced Studies Institute series 'Drug Targeting' and 'Vaccines' (1981-1999), his founding of the 'Liposome Advances' conference series (1991-2013), and his position of Professor Emeritus at University College London. He is in charge of the International Liposome Society(since 2003).

Drug Delivery Research

Urszula Kosikowska (PhD) is a pharmacist, specialist in medical microbiology. She is a lecturer in the Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, Poland. She has published scientific publications in reputed journals, as well as a monography, popular articles and conference reports. Her research interests include issues of respiratory microbiota, diagnostics and drug resistance of bacteria and antimicrobial activity of newly synthesized compounds on planktonic and biofilm-forming cells mainly of the genus Haemophilus and other selected members of the family Pasteurellaceae.

Medical Microbiology

Lee Truax-Bellows is a Founder, President and CEO of Norwich Clinical Research Associates Ltd. (NCRA). NCRA is a full service clinical contract research organization (CRO) based in upstate NY. She has an extensive background in the pharmaceutical and medical device industries, having worked for both industry and a CRO as a Monitor, Medical Communications Associate, Project Manager, Senior Quality Auditor, GCP Trainer, and Regulatory and SOP Consultant. She has been involved in regulated research the past 25 years and currently specializes in product development, GCP auditing, and SOP development and training on regulated research and Good Clinical Practice. She is an active member of the Association of Clinical Research Professionals (ACRP), New York State MedTech Association and Society of Quality Assurance (SQA). She is ACRP certified as a Certified Clinical Research Associate (CCRA) and registered through SQA as a Registered Quality Assurance Professional in Good Clinical Practices (RQAP-GCP).

Product development, GCP auditing and SOP development

Dr. Weiguo Dai is a Scientific Director and Janssen Fellow at Johnson and Johnson. He has been recognized for his innovative and outstanding contributions that have had a significant impact on the areas of patient-centered drug delivery technology and delivery-enhanced drug product development. He has a proven track record of driving products from concept to development and commercialization. Dr. Dai’s research and innovation have primarily focused on improving the drug efficacy, safety, and patient compliance through the design and development of novel formulations, and delivery technologies and processes. His technology innovations have directly led to the launch of delivery-enhanced commercial products. As a well-recognized industrial expert, Dr. Dai has made influential and sustained contributions in the areas of developing new oral controlled delivery technologies, novel delivery technologies for sustained release of biologics, enhanced delivery systems for biologics product differentiation and life cycle management, and applying enabling delivery technologies for drug products in the development pipeline.

Drug delivery technology